Swiss drug manufacturer to purchase Põlva packaging plant ({{commentsTotal}})


Drug manufacturer Takeda Pharmaceutical Company is slated to sell drug packaging plant Takeda Pharma AS, located in Põlva, to Swiss drug manufacturer Acino.

According to Takeda Pharma AS plant manager Katrin Madissoo, the plant will continue to provide packaging services for Takeda as well for a period of three years, during which the former parent company's products will gradually be switched out for Acino products, reported Estonian daily Eesti Päevaleht.

Last fall, Takeda announced that it was planning to sell its plant in Põlva in order to further optimize its worldwide production network. The Põlva plant was recommended to seek a strategic partner, and a condition was set that the new owners must be prepared to take over the plant in such a way that it would continue to operate in the future as well.

In mid-July, Takeda announced that a buyer had been found and contract signed, and that the new owner would be the nearly 1,300-employee Swiss drug manufacturer Acino.

The Põlva plant's 2014 and 2015 sales revenue and net profit totaled 25,743,000 euros and 929,000 euros, respectively.

The plant's target markets include the Baltic States, Europe and Russia, while the drugs packaged at the plant are brought in from the corporation's manufacturing plants in Germany, Denmark and Poland.

Editor: Editor: Aili Sarapik

+{{cc.replyToName}} {{cc.body}}
No comments yet.
Logged in as {{user.alias}}. Log out
Login failed

Register user/reset password

Name needs to be fewer than 32 characters long
Comment needs to be fewer than 600 characters long

Lotman: Security academy would be crucial Estonian identity point in Narva

In an opinion piece published by Eesti Päevaleht, Tallinn University professor Mihhail Lotman found it important to overcome the mental barrier separating Ida-Viru County from the rest of Estonia.

Ermamaa: The fine art of passing the buck

Admit nothing, blame everyone: those most closely involved in the Ermamaa case don’t need arguments, writes ERR News editor Dario Cavegn.